23 Jan IN8bio
Kate Rochlin, Chief Operating Officer
April 12 | 10:45am | BioCentriq Ballroom
New York, NY
(NASDAQ: INAB)
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. Our platform employs allogeneic, autologous, iPSCs, and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. We are one of the most advanced gamma-delta T cell companies and the first to bring genetically modified gamma-delta T cells into the clinic. Our lead product candidates are currently in Phase I clinical trials: INB-200, for the treatment of newly diagnosed glioblastoma, or GBM, and INB-100, for the treatment of patients with leukemia that are undergoing hematopoietic stem cell transplantation, or HSCT. Our platform has yielded a broad portfolio of preclinical and discovery-stage programs, focused on addressing solid tumors.
